- Home
- CCEC vs AUPH Comparison
CCEC vs AUPH Comparison
Compare CCEC & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEC
- AUPH
- Stock Information
- Founded
- CCEC 2007
- AUPH 1993
- Country
- CCEC Greece
- AUPH Canada
- Employees
- CCEC N/A
- AUPH N/A
- Industry
- CCEC Marine Transportation
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- CCEC Consumer Discretionary
- AUPH Health Care
- Exchange
- CCEC Nasdaq
- AUPH Nasdaq
- Market Cap
- CCEC 1.1B
- AUPH 999.8M
- IPO Year
- CCEC 2007
- AUPH 1999
- Fundamental
- Price
- CCEC $17.00
- AUPH $7.75
- Analyst Decision
- CCEC Buy
- AUPH Strong Buy
- Analyst Count
- CCEC 2
- AUPH 2
- Target Price
- CCEC $24.00
- AUPH $11.50
- AVG Volume (30 Days)
- CCEC 16.5K
- AUPH 1.3M
- Earning Date
- CCEC 04-29-2025
- AUPH 05-01-2025
- Dividend Yield
- CCEC 3.53%
- AUPH N/A
- EPS Growth
- CCEC 20.78
- AUPH N/A
- EPS
- CCEC 2.60
- AUPH 0.04
- Revenue
- CCEC $369,413,000.00
- AUPH $235,133,000.00
- Revenue This Year
- CCEC $19.13
- AUPH $11.86
- Revenue Next Year
- CCEC $20.93
- AUPH $24.96
- P/E Ratio
- CCEC $139.82
- AUPH $193.75
- Revenue Growth
- CCEC 2.45
- AUPH 33.97
- 52 Week Low
- CCEC $14.09
- AUPH $4.71
- 52 Week High
- CCEC $20.40
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- CCEC N/A
- AUPH 46.63
- Support Level
- CCEC N/A
- AUPH $7.59
- Resistance Level
- CCEC N/A
- AUPH $7.83
- Average True Range (ATR)
- CCEC 0.00
- AUPH 0.35
- MACD
- CCEC 0.00
- AUPH -0.02
- Stochastic Oscillator
- CCEC 0.00
- AUPH 65.84
About CCEC Capital Clean Energy Carriers Corp. Common Share
Capital Clean Energy Carriers Corp is an international shipping company. It is the leading platform of gas carriage solutions with a focus on the energy transition. The company owns 20 high-specification vessels, including 12 latest-generation LNG carriers (LNG/Cs) and eight legacy Neo-Panamax container vessels.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.